Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study

Bernard Canaud1, Giulio Mingardi2, Johann Braun3, Pedro Aljama4, Peter G. Kerr5, Francesco Locatelli6, Giuseppe Villa7, Bruno Van Vlem8, Alan W. McMahon9, Cécile Kerloëguen10 and Ulrich Beyer10 on behalf of the STRIATA Study Investigators

1Service de Nephrologie, Hôpital Lapeyronie, Montpellier, France, 2Unita’ Operativa di Nefrologia e Dialisi, Ospedali Riuniti di Bergamo, Bergamo, Italy, 3KFH-Dialysezentrums, Nuernberg, Germany, 4Hospital Reina Sofia, Servicio de Nefrologia, Cordoba, Spain, 5Department of Nephrology, Monash Medical Centre, Clayton, Australia, 6Divisione di Nefrologia e Dialisi, Azienda Ospedale di Lecco, Lecco, Italy, 7Divisione di Nefrologia e Dialisi, Fondazione ‘S. Maugeri’ IRCCS, Pavia, Italy, 8Department of Nephrology, Dialysis and Hypertension, O.L. Vrouw Ziekenhuis, Aalst, Belgium, 9University of Alberta Hospital, Edmonton, Canada and 10F. Hoffmann-La Roche Ltd, Basel, Switzerland

Abstract
Background. Extending the administration interval of erythropoiesis-stimulating agents (ESAs) represents an opportunity to improve the efficiency of anaemia management in patients with chronic kidney disease (CKD). However, effective haemoglobin (Hb) maintenance can be challenging with epoetin alfa and epoetin beta administered at extended intervals. C.E.R.A., a continuous erythropoietin receptor activator, has a unique pharmacologic profile and long half-life (~130 h), allowing administration at extended intervals. Phase III results have demonstrated that C.E.R.A. administered once every 4 weeks effectively maintains stable Hb levels in patients with CKD on dialysis.

Methods. STRIATA (Stabilizing haemoglobin TaRgets in dialysis following IV C.E.R.A. Treatment for Anaemia) was a multicentre, open-label randomized phase III study to evaluate the efficacy and safety of intravenous C.E.R.A. administered once every 2 weeks (Q2W) for Hb maintenance following direct conversion from darbepoetin alfa (DA). Adult patients on dialysis receiving stable intravenous DA once weekly (QW) or Q2W were randomized (1:1) to continue their current DA regimen (n = 156) or receive intravenous C.E.R.A. Q2W (n = 157) for 52 weeks. Doses were adjusted to maintain Hb levels within ±1.0 g/dl of baseline and between 10.0 and 13.5 g/dl. The primary endpoint was the mean Hb change between baseline and the evaluation period (weeks 29–36).

Results. Most patients (>80%) received DA QW before randomization. The mean (95% CI) difference between C.E.R.A. and DA in the primary endpoint was 0.18 g/dl (−0.05, 0.41), within a pre-defined non-inferiority limit. C.E.R.A. was clinically non-inferior to DA (P < 0.0001) in maintaining Hb levels. Both treatments were well tolerated.

Conclusions. Stable Hb levels were successfully maintained in patients on haemodialysis directly converted to Q2W intravenous C.E.R.A. from DA.

Keywords: anaemia; C.E.R.A.; darbepoetin alfa; dialysis; haemoglobin

Introduction
Anaemia secondary to chronic kidney disease (CKD) is associated with increased hospitalization and decreased survival [1,2], increased burden of cardiovascular disease [3,4] and reduced quality of life [5,6]. Despite improvements, large observational studies such as the Dialysis Outcomes and Practice Patterns Study (DOPPS) indicate that anaemia remains prevalent in patients receiving dialysis; therefore, there is a need to increase the proportions of patients achieving guideline haemoglobin (Hb) targets [7]. With the growing prevalence of CKD [8,9], new approaches are required to improve the efficiency of anaemia management without increasing the workload of healthcare staff.

Extended administration intervals represent an opportunity to simplify treatment and improve the efficiency of anaemia management. For example, the preliminary results of a recent observational study indicated that extending the administration interval from three times weekly to once...
weekly (QW) was associated with substantial time savings [10]. It was estimated that 350 h of physician/nurse time per year could be saved in a centre with 50 dialysis patients. Extended administration intervals may also offer benefits for patients with CKD. If administration intervals could be successfully extended beyond QW for all patients, the resulting time savings could enable healthcare providers to spend more time focusing on other aspects of CKD management, including patient education, and to address other modifiable risk factors, such as hypertension and mineral balance.

C.E.R.A., a continuous erythropoietin receptor activator, is indicated in the European Union for once-monthly maintenance of Hb levels in patients with CKD. C.E.R.A. has different receptor binding characteristics to established erythropoiesis-stimulating agents (ESAs) [11,12] and a long half-life of \(~130\) h following intravenous and subcutaneous administration [13]. In phase II and phase III studies in patients with CKD on dialysis, C.E.R.A. effectively maintained stable Hb levels when administered once every 4 weeks (Q4W) [14–16].

STRIATA (Stabilizing haemoglobin TaRgets in dialysis following IV C.E.R.A. Treatment for Anaemia) was a multicentre, open-label randomized phase III study designed to investigate the efficacy and safety of intravenous C.E.R.A. Q2W for Hb maintenance in patients on dialysis who converted directly from intravenous DA QW or Q2W.

We report the primary efficacy and safety results from STRIATA.

**Patients and methods**

**Patients**

Adult patients with chronic renal anaemia receiving adequate haemodialysis (Kt/V \(\geq 1.2\) or urea reduction ratio \(\geq 65\)% or peritoneal dialysis (weekly Kt/V \(\geq 1.8\)) for \(\geq 12\) weeks and intravenous DA therapy at the same administration interval (either QW or Q2W) for \(\geq 8\) weeks were eligible for screening.

Patients had stable mean baseline Hb levels (difference between mean individual Hb values at the beginning and end of the run-in period \(\leq 1\) g/dl) of between 10.5 and 13.0 g/dl. The values for Hb entry criteria were within the ranges recommended by anaemia treatment guidelines at the time the study was designed [17,18]. Adequate iron status (serum ferritin \(\geq 100\) ng/ml or transferrin saturation \(\geq 20\)% or hypochromic red cells \(<10\)%) was also required for study entry.

Patients were excluded if they had non-renal causes of anaemia (e.g. folic acid or vitamin B\(_{12}\) deficiency, haemolysis and haemoglobinopathies), C-reactive protein \(>30\) mg/l or life expectancy \(<12\) months.

The study was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice guidelines and was approved by local ethics committees. All study participants provided written informed consent.

**Study drugs**

C.E.R.A. (F. Hoffmann-La Roche Ltd, Basel, Switzerland) was provided as a sterile injectable solution in 2 ml single-use glass vials containing 1 ml solution. The solution was available in 50, 100, 200, 400 and 1000 \(\mu\)g/ml concentrations.

DA (Amgen Inc., Thousand Oaks, USA) was obtained commercially in pre-filled syringes.

**Study design**

STRIATA was a multicentre, parallel-group, open-label, randomized phase III study designed to investigate the efficacy and safety of intravenous C.E.R.A. Q2W for Hb maintenance in patients on dialysis who converted directly from intravenous DA QW or Q2W.

After a 4-week run-in period during which patients continued to receive DA, patients were randomized (1:1) to receive intravenous C.E.R.A. Q2W or to continue their intravenous DA regimen (Figure 1). Patients were randomly assigned to one of the two treatment groups by a central randomization centre. For each study centre, randomization numbers were allocated sequentially to each patient in the order in which they were enrolled.

The starting doses of C.E.R.A. were selected based on the results of phase II studies and calculated by patient according to their DA dose before randomization (Table 1). A period of 28 weeks after the first dose of study drug was used for dose titration. This was followed by an 8-week efficacy evaluation period (weeks 29–36), and a further 16-week safety observation period (weeks 37–52; Figure 1).

During the dose-titration and evaluation periods, doses of trial medication were adjusted according to Hb response. The aim was to maintain individual patients’ Hb within \(\pm 1.0\) g/dl of their baseline level, and to maintain absolute

**Table 1. Starting doses of C.E.R.A.**

| Previous DA dosage (\(\mu\)g/week) | C.E.R.A. starting dosage (\(\mu\)g/2 weeks) |
|-------------------------------------|------------------------------------------|
| \(<40\)                             | 60                                       |
| 40–80                               | 100                                      |
| \(>80\)                             | 180                                      |

DA, darbepoetin alfa.
Hb values for the overall study population between 10.0 and 13.5 g/dl. During the safety observation period, doses were adjusted to maintain the Hb levels within 11–13 g/dl. It should be noted that the target Hb ranges chosen for this study were agreed by consensus of the Steering Committee based on contemporary anaemia treatment guidelines; the study was completed before the publication of the CHOIR study which prompted safety concerns regarding the maintenance of Hb levels >13 g/dl [19].

Dose adjustments were permitted for safety at any point during the study. Unless safety concerns dictated otherwise, dose adjustments were performed at the next scheduled dosing day so that the administration interval remained unchanged throughout the study. In addition, dose adjustments for C.E.R.A. were not performed more frequently than once every 4 weeks. Dose adjustments for DA were performed according to its approved labelling (i.e. 25% dose increase or decrease based on the Hb value), but maintaining the target Hb and the interval between dose adjustments the same as for C.E.R.A. Patients received intravenous iron supplementation as required throughout the run-in and treatment periods.

Study parameters

The primary efficacy parameter was the change in mean Hb levels between baseline and the evaluation period. Secondary efficacy parameters were the proportion of patients maintaining Hb within ±1 g/dl of baseline during the evaluation period and the incidence of red blood cell (RBC) transfusions during the dose-titration and evaluation periods. Additional efficacy parameters included mean Hb over time, mean Hb by study period, intrapatient Hb variability (mean within-patient standard deviations for Hb) during the dose titration, evaluation and safety observation periods and the number of patients requiring dose adjustments. Safety parameters included adverse event (AE) reporting, vital signs, laboratory haematology and blood chemistry (including iron), immunogenicity testing and electrocardiograms.

Assessments

Patients were assessed weekly during the screening/baseline, dose-titration and evaluation periods, and every other week during the safety observation period. Hb levels, blood pressure, heart rate, iron status and other safety laboratory parameters were assessed throughout the study. Blood samples were collected for anti-erythropoietin antibody testing at weeks 1, 13, 29 and 41 and at the final visit.

AEs were recorded during the randomized treatment period and RBC transfusions and iron supplementation were recorded throughout the study.

Statistical analysis

A sample size of 264 patients (≥132 patients per treatment group) was required to test with 90% power the hypothesis that C.E.R.A. Q2W was non-inferior to DA (primary efficacy parameter). This assumes a true difference between the C.E.R.A. and DA groups not greater than 0.3 g/dl, a common standard deviation for both groups of 1.0 g/dl and a drop-out/major protocol violation rate of 20%.

Non-inferiority was tested by calculating the difference in the primary efficacy parameter (mean Hb change between baseline and the evaluation period) for patients randomized to treatment with C.E.R.A. and DA. Two-sided 95% confidence intervals (CIs) for this difference were calculated by analysis of covariance (ANCOVA), using treatment group as the independent variable and adjusting for covariates that might influence Hb response (baseline Hb and geographic region). Non-inferiority of C.E.R.A. versus DA could be concluded if the lower limit of the 95% CI was ≥-0.75 g/dl. In setting the -0.75 g/dl Hb threshold for the lower limit of the 95% CI (around the mean group difference), it was expected that the observed mean difference between the groups would be markedly <0.75 g/dl (according to the anticipated level of variability) and at a level not regarded as being clinically significant.

The primary efficacy analysis was conducted on the per-protocol (PP) population (patients without major protocol violations or withdrawal) and was confirmed on the intent-to-treat (ITT) population (all randomized patients).

Secondary and additional efficacy analyses were performed on the ITT population and summarized using descriptive methods. The last observation carried forward approach was used for missing data. In the case of RBC transfusions, the Hb value measured before the transfusion was used. Safety assessments, which included AE reporting, laboratory assessments of iron parameters and blood chemistry and monitoring of vital signs, were examined in the safety population (all patients who received at least one dose of study medication and had a safety follow-up assessment), and group summary statistics were calculated.

Results

Patients

Patients were recruited from 48 centres in 12 countries in Europe, Australia and Canada. The disposition of enrolled patients is shown in Figure 2. The ITT population comprised 313 patients who were randomized to C.E.R.A. Q2W (n = 157) or DA at their continued weekly dose and interval (n = 156). The PP population comprised 249 patients. The main reasons for exclusion from the PP population were less than five Hb values measured during evaluation (n = 37), inadequate iron status at baseline and during evaluation or no valid iron assessments (n = 29) and RBC transfusions within weeks 20–32 (n = 17). In addition, four patients in the C.E.R.A. group withdrew before receiving any study medication [protocol violation (n = 1), refused treatment (n = 1), failed to return (n = 2)] and were not included in the safety population.

Most patients (n = 249) completed the study. Reasons for premature withdrawal from the study included death (12 and 10 patients in the C.E.R.A. and DA groups, respectively), transplantation (14 and 6 patients treated with C.E.R.A. and DA, respectively), refusal of treatment (four
The remaining 11 patients (C.E.R.A., n = 4; C.E.R.A., kidney transplantation (C.E.R.A., n = 6) failed to return (C.E.R.A., n = 3) and failure to return (C.E.R.A., n = 2). The remaining 11 patients (C.E.R.A., n = 6; DA, n = 5) withdrew for reasons that included patient vacation, patient decision, patient instability (poor medical condition), protocol violation, discontinuation of dialysis, enrollment in nocturnal haemodialysis study and starting home dialysis. DA, darbepoetin alfa; QW, once weekly; Q2W, once every 2 weeks; ITT, intent-to-treat; PP, per-protocol; AE, adverse event.

Baseline characteristics were similar between treatment groups (Table 2) and were generally representative of the dialysis population. The primary causes of CKD in each treatment group were diabetes (24.0%), glomerulonephritis (23.0%) and hypertension/large vessel disease (21.4%) (Table 2). Before randomization, 82.2% of patients in the C.E.R.A. group and 84.0% DA group were receiving DA at weekly intervals (Table 2). There were slightly more male patients in the C.E.R.A. group (Table 2). Mean Hb levels at baseline were similar in patients randomized to C.E.R.A. (12.0 g/dl) and DA (11.9 g/dl). Most patients were undergoing haemodialysis with arteriovenous fistula and had been receiving dialysis for ∼3.5 years (Table 2); one patient was receiving peritoneal dialysis (DA group). Arteriovenous grafts and catheters were slightly more common in the DA group (Table 2). Similar proportions of patients in each group received angiotensin-converting enzyme inhibitors and angiotensin-II receptor antagonists.

Efficacy evaluation

Mean Hb levels during the evaluation period were similar between treatment groups (Table 3; Figure 3): 12.1 g/dl for C.E.R.A. and 11.8 g/dl for DA (Table 3). Adjusted mean changes in Hb between baseline and the evaluation period (PP population) were 0.06 g/dl for C.E.R.A. and −0.12 g/dl for DA with the mean (95% CI) difference between groups being 0.18 g/dl (−0.05, 0.41) (Figure 4). The lower limit of the 95% CI was considerably greater than the pre-defined −0.75 g/dl non-inferiority threshold, demonstrating that C.E.R.A. was non-inferior to DA for the maintenance of Hb levels (P < 0.0001). Comparable results were obtained when the test was repeated in the ITT population (Figure 4).

During the evaluation period, mean Hb values were maintained within +1 g/dl of baseline in a similar proportion of patients treated with C.E.R.A. and DA (65.5 and 71.8% of patients in the C.E.R.A. and DA groups, respectively, P = 0.2502, chi-square test). Assessment of the mean standard deviation of Hb revealed similar intrapatient Hb variability in the C.E.R.A. and DA groups during the titration (0.86 versus 0.76 g/dl), evaluation (0.63 versus 0.53 g/dl) and safety observation (0.71 versus 0.66 g/dl) periods (Figure 5). These findings are consistent with the primary efficacy assessment and support the view that Hb control was successfully maintained following conversion to C.E.R.A. in patients who were predominantly (>80%) receiving QW DA before randomization.

Iron parameters were well maintained in both treatment groups (Table 4). Concomitant iron supplementation was administered to 92% of patients treated with C.E.R.A. and 93% of those receiving DA. The most frequently used iron supplements were iron sucrose and ferrous gluconate.

Similar proportions of patients required at least one RBC transfusion during the dose-titration and evaluation periods: C.E.R.A. (12.4%) and DA (10.3%). Assessment of doses of trial medication revealed that baseline median doses were 0.49 µg/kg/week [interquartile range (IQR): 0.43–0.73] for C.E.R.A. and 0.44 µg/kg/week.
Table 2. Baseline characteristics (intent-to-treat population)

| Characteristic                                      | C.E.R.A. (n = 157) | DA (n = 156) |
|-----------------------------------------------------|--------------------|--------------|
| Male, n (%)                                         | 100 (64)           | 81 (52)      |
| Mean age, year (± SD)                               | 62.4 (16.17)       | 61.8 (14.74) |
| Mean weight, kg (± SD)                              | 68.9 (16.69)       | 70.3 (16.50) |
| Mean Hb, g/dl (± SD)                                | 12.0 (0.7)         | 11.9 (0.7)   |
| Median TSAT, % (IQR)                                | 28.4 (22.3–35.3)   | 28.0 (21.6–33.5) |
| Median ferritin, µg/l (IQR)                         | 367.8 (216–547)    | 382.3 (233–596) |
| Primary cause of CKD (incidence ≥5%) (%)            |                    |              |
| Diabetes                                            | 25                 | 22           |
| Glomerulonephritis                                  | 25                 | 21           |
| Hypertension/large vessel disease                   | 24                 | 19           |
| Interstitial nephritis/peyelonephritis              | 8                  | 16           |
| Undefined aetiology                                 | 6                  | 9            |
| Secondary glomerulonephritis/vasculitis             | 6                  | 6            |
| Polycystic kidney disease                           | 4                  | 5            |
| Other hereditary/congenital disease                 | 5                  | <1           |
| Previous DA schedule, n (%)                         |                    |              |
| QW                                                  | 129 (82.2)         | 131 (84.0)   |
| Q2W                                                 | 28 (17.8)          | 25 (16.0)    |
| Mean Kt/Va (± SD)                                   | 1.57 (0.33)        | 1.57 (0.34)  |
| Vascular access type, n (%)                         |                    |              |
| Arteriovenous fistula                               | 132 (84.1)         | 117 (75.5)   |
| Arteriovenous graft                                 | 18 (11.5)          | 26 (16.8)    |
| Indwelling (tunnelled) catheter                     | 7 (4.5)            | 12 (7.7)     |
| Median time since first dialysis (days)             | 1254               | 1319         |

*Safety population.

DA, darbepoetin alfa; SD, standard deviation; Hb, haemoglobin; TSAT, transferrin saturation; IQR, interquartile range; CKD, chronic kidney disease; QW, once weekly; Q2W, once every 2 weeks.

Table 3. Mean Hb by study period (per-protocol population)

| Period                      | n   | Mean (SD) Hb level (g/dl) |
|-----------------------------|-----|--------------------------|
| Baseline (weeks −4 to 0)    |     |                          |
| C.E.R.A.                    | 123 | 12.0 (0.7)               |
| DA                          | 126 | 11.9 (0.6)               |
| Titration (weeks 0 to 28)   |     |                          |
| C.E.R.A.                    | 123 | 12.3 (0.7)               |
| DA                          | 126 | 11.9 (0.7)               |
| Evaluation (weeks 29 to 36) |     |                          |
| C.E.R.A.                    | 123 | 12.1 (1.0)               |
| DA                          | 126 | 11.8 (1.0)               |
| Safety (weeks 37 to 52)     |     |                          |
| C.E.R.A.                    | 120 | 11.7 (1.1)               |
| DA                          | 124 | 11.7 (1.0)               |

DA, darbepoetin alfa; Hb, haemoglobin; SD, standard deviation.

Table 4. Median ferritin and transferrin saturation by study period (safety population)

| Period                      | Median (IQR) ferritin (ng/ml) | Median (IQR) TSAT (%) |
|-----------------------------|-------------------------------|-----------------------|
| Baseline (weeks −4 to 0)    |                               |                       |
| C.E.R.A.                    | 368 (216–543)                 | 28.2 (22.0–35.0)      |
| DA                          | 382 (231–596)                 | 28.0 (21.9–33.5)      |
| End of evaluation (week 36) |                               |                       |
| C.E.R.A.                    | 357 (223–569)                 | 29.0 (22.5–36.7)      |
| DA                          | 402 (251–635)                 | 25.9 (21.0–32.0)      |
| End of study (week 52)      |                               |                       |
| C.E.R.A.                    | 405 (282–614)                 | 25.9 (21.0–32.0)      |
| DA                          | 400 (241–577)                 | 25.8 (19.5–34.0)      |

DA, darbepoetin alfa; IQR, interquartile range; TSAT, transferrin saturation.

*Fig. 5. Individual stability of Hb mean levels (intent-to-treat population). No formal test was conducted to assess the statistical significance of between-group differences; however, the overlapping SD bars suggest any difference would not be significant. DA, darbepoetin alfa; QW, once weekly; Q2W, once every 2 weeks.*
Safety and tolerability

The overall incidences of AEs, serious AEs and AEs leading to withdrawal and deaths were similar between the two treatment groups and typical of the patient population (Table 5). At least one AE was experienced by 88% and 92% of patients in the C.E.R.A. and DA groups, respectively, although most events were mild or moderate in intensity. The most commonly reported AEs were diarrhoea, nasopharyngitis and influenza (Table 5). AEs leading to withdrawal occurred in one patient in each treatment group (hypertensive encephalopathy in the C.E.R.A. group and peripheral ischaemia in the DA group).

Serious AEs were experienced by 46% and 48% of patients in the C.E.R.A. and DA groups, respectively. Serious AEs were considered to be related to study treatment in one patient in the C.E.R.A. group (arteriovenous graft thrombosis) and three patients in the DA group (arteriovenous graft thrombosis, arteriovenous fistula site haemorrhage and cerebral infarction).

Twenty-five deaths occurred in the study (13 C.E.R.A. patients and 12 DA patients; Tables 5 and 6), including three deaths of patients who had been withdrawn for other reasons. AEs were considered related to study treatment in one patient (the C.E.R.A. group) and three patients in the DA group (arteriovenous graft thrombosis, arteriovenous fistula site haemorrhage and cerebral infarction). No AE resulted in death and the majority of deaths in patients treated with both C.E.R.A. and DA were associated with maximum Hb levels ≥11 g/dl within the 2 weeks before death.

Safety and tolerability

The overall incidences of AEs, serious AEs and AEs leading to withdrawal and deaths were similar between the two treatment groups and typical of the patient population (Table 5). At least one AE was experienced by 88% and 92% of patients in the C.E.R.A. and DA groups, respectively, although most events were mild or moderate in intensity. The most commonly reported AEs were diarrhoea, nasopharyngitis and influenza (Table 5). AEs leading to withdrawal occurred in one patient in each treatment group (hypertensive encephalopathy in the C.E.R.A. group and peripheral ischaemia in the DA group).

Serious AEs were experienced by 46% and 48% of patients in the C.E.R.A. and DA groups, respectively. Serious AEs were considered to be related to study treatment in one patient in the C.E.R.A. group (arteriovenous graft thrombosis) and three patients in the DA group (arteriovenous graft thrombosis, arteriovenous fistula site haemorrhage and cerebral infarction).

Twenty-five deaths occurred in the study (13 C.E.R.A. patients and 12 DA patients; Tables 5 and 6), including three deaths of patients who had been withdrawn for other reasons. AEs were considered related to study treatment in one patient (the C.E.R.A. group) and three patients in the DA group (arteriovenous graft thrombosis, arteriovenous fistula site haemorrhage and cerebral infarction).

Table 5. Overall and most frequent adverse events (≥8% of patients) (safety population)

| Event                        | C.E.R.A. (n = 153) | DA (n = 156) |
|------------------------------|-------------------|-------------|
| Diarrhoea                    | 24 (16)           | 16 (10)     |
| Nasopharyngitis              | 19 (12)           | 16 (10)     |
| Influenza                    | 19 (12)           | 12 (8)      |
| Fluid overload               | 14 (9)            | 13 (8)      |
| Cough                        | 14 (9)            | 12 (8)      |
| Hypertension                 | 13 (8)            | 12 (8)      |
| Back pain                    | 11 (7)            | 13 (8)      |
| Vomiting                     | 10 (7)            | 13 (8)      |
| Upper respiratory tract infec| 9 (6)             | 12 (8)      |
| Headache                     | 8 (5)             | 12 (8)      |
| Angina pectoris              | 12 (8)            | 7 (4)       |
| Pyrexia                      | 12 (8)            | 6 (4)       |
| Any adverse event            | 135 (88.2)        | 143 (91.7)  |
| Serious adverse events       | 71 (46.4)         | 75 (48.1)   |
| Adverse events leading to withdrawal | 1 (0.7) | 1 (0.6) |
| Deaths*                      | 13 (8.5)          | 12 (7.7)    |

*Includes three deaths of patients who had been withdrawn for other reasons.

DA, darbepoetin alfa.

Table 6. Listing of all deaths during the study ranked by maximum Hb level within the 2 weeks before death (safety population)

| Maximum Hb within previous 2 weeks (g/dl) | Cause of death (randomization group) |
|------------------------------------------|-------------------------------------|
| 8.5                                      | Cachexia (DA)                       |
| 8.7                                      | Malignant lung neoplasm (C)         |
| 8.8                                      | Sepsis (DA)                         |
| 8.9                                      | Cardio-respiratory arrest (C)       |
| 9.5                                      | Cachexia (DA)                       |
| 9.7                                      | Septic shock (C)                    |
| 10.3                                     | Infection (DA)                      |
| 10.8                                     | Sepsis (C)                          |
| 10.5                                     | Chronic renal failure (DA)          |
| 10.6                                     | Chronic renal failure (DA)          |
| 10.8                                     | Atherosclerosis (C)                 |
| 11.0                                     | Cardiac arrest (DA)                 |
| 11.3                                     | Sudden death (C)                    |
| 11.6                                     | Pneumonia (C)                       |
| 12.0                                     | Calciphylaxis (C)                   |
| 12.1                                     | Cardiac arrest (DA)                 |
| 12.1                                     | Cerebrovascular accident (DA)       |
| 12.2                                     | Enterococcal sepsis (DA)            |
| 12.3                                     | Pneumonia aspiration (DA)           |
| 12.6                                     | Cardiopulmonary failure (C)         |
| 12.9                                     | Cerebrovascular accident (DA)       |
| 14.8                                     | Ventricular fibrillation (C)        |
| 14.9                                     | Intestinal infarction (C)           |
| 15.6                                     | Cerebral haemorrhage (C)            |

*Maximum Hb level within the 4 weeks before death. Light shading denotes maximum Hb levels <11 g/dl within the 2 weeks before death; no shading denotes maximum Hb levels between 11 and 12 g/dl; dark shading maximum Hb levels >12 g/dl. C, C.E.R.A.; DA, darbepoetin alfa.

Discussion

These findings from STRIATA demonstrate that patients receiving haemodialysis can be successfully converted to Q2W intravenous C.E.R.A. from intravenous DA maintenance therapy. In addition, the results confirm that the simple dosing conversion scheme based on previous DA dose was effective in providing stable Hb maintenance for patients converting from DA to Q2W C.E.R.A. Patients in STRIATA successfully maintained mean Hb levels within the 10.0–13.5 g/dl target range, with the primary efficacy analysis demonstrating non-inferiority of C.E.R.A. relative to DA (P < 0.0001) for Hb maintenance in patients receiving dialysis.

Important features of this study are the randomized, parallel-group design and the inclusion of patients with considerable co-morbidities, which can be considered representative of the general dialysis population. The study design was conceived and developed with the intention of testing the hypothesis that intravenous C.E.R.A. is non-inferior to intravenous DA for Hb maintenance in patients on dialysis. The study recruited patients who had undergone previous anaemia treatment to Hb levels within the target ranges recommended by contemporary guidelines [17,18], and the aim was to maintain Hb levels within similar target ranges following randomization.

Since the completion of STRIATA, new evidence has become available which has prompted safety concerns over
the targeting of Hb levels >13 g/dl [19,20]. While no correlations between Hb concentrations and safety outcomes were observed in STRIATA, the study was not designed to address such questions. The results from STRIATA suggest that Q2W intravenous C.E.R.A. can maintain Hb levels within a specified target range as effectively as intravenous DA.

During the evaluation period, Hb was maintained within ±1 g/dl of baseline in approximately two-thirds of patients, and intrapatient Hb variability, a measure of individual stability of Hb levels, was comparable between treatment groups during the titration, evaluation and safety observation periods. It is noteworthy that while patients in the reference group, who had previously been maintained on DA, continued to be successfully maintained, those patients randomized to C.E.R.A. also maintained stable Hb levels despite the change in therapy and, in most patients, treatment interval.

RBC transfusions, which were assessed as a secondary efficacy parameter, were low and similar across treatment groups supporting the non-inferiority result obtained in the primary efficacy analysis. The observed transfusion rates of 10–12% are consistent with those reported by other investigators in a similar patient population [21]. C.E.R.A. was generally well tolerated, with a similar safety profile to that of DA. Most AEs were considered to be unrelated to study medication and were consistent with common AEs associated with this patient population. Considered together, these findings indicate that Q2W intravenous C.E.R.A. offers comparable Hb control with similar safety and tolerability to the comparator DA.

Anaemia is a common complication of CKD, and despite advances in care since the introduction of the first ESAs, further improvements in the proportions of patients achieving and maintaining guideline targets for Hb concentration are still possible [7,22]. Moreover, within the context of clinical practice, there is a need to optimize the efficiency of anaemia management to ensure that nephrology clinics can continue to provide effective care for a growing patient population. One approach to realizing such efficiency is to reduce the administration frequency of ESAs. Preclinical and pharmacokinetic studies indicate that the pharmacokinetic and pharmacodynamic profile of C.E.R.A. may enable administration at extended intervals [12,13]. This hypothesis is supported by the results from STRIATA, as well as other phase III [15,16] and phase II [14] clinical studies, in which intravenous and subcutaneous C.E.R.A. effectively maintained Hb levels in patients with CKD on dialysis when administered Q4W.

In summary, results from STRIATA confirm that stable Hb levels can be maintained with comparable variability in patients with CKD on haemodialysis who convert to intravenous C.E.R.A. Q2W from intravenous DA QW or Q2W. The time savings estimated to arise from reductions in administration frequency [10] could represent an important benefit in clinical practice, facilitating greater efficiency of anaemia management and enabling healthcare providers to devote more time to other aspects of patient care. Although the debate surrounding optimal Hb targets is ongoing and further evolution of anaemia treatment guidelines is anticipated, the findings from STRIATA should offer confidence that intravenous C.E.R.A. can maintain stable Hb levels within a pre-specified target range.

Acknowledgements. STRIATA was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Data analyses were conducted by the sponsor. Responsibility for opinions, conclusions and interpretation of data lies with the authors. Medical writing support during the preparation of this paper was provided by Emma Marshman, Mark Waterlow and Annette Njué-Doswell at Prime Medica Ltd, supported by F. Hoffmann-La Roche Ltd.

Conflict of interest statement. Data from this study have been presented previously in the following published abstract: Canaud B, Braun J, Locatelli F et al, on behalf of the STRIATA study investigators: Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 week maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. *Nephrol Dial Transplant* 2006; 21: iv157 (abstract SP425).

Professor Canaud has received consultancy fees from Amgen, Baxter, F. Hoffmann-La Roche Ltd, Fresenius Medical Care, Janssen-Cilag, Medcomp and Shire; he does not hold stock in any company with interests in nephrology. The Institut de Recherche et de Formation en Dialyse affiliated to the Service de Néphrologie has received research grants from several companies including F. Hoffmann-La Roche Ltd.

Dr Mingardi has received honoraria and consultancy fees from F. Hoffmann-La Roche Ltd; he does not hold stock in any company with interests in nephrology. The Unità’ Operativa di Nefrologia e Dialisi Ospedali Riuniti di Bergamo has received research grants from F. Hoffmann-La Roche Ltd.

Professor Braun has received honoraria and research grants from Amgen, F. Hoffmann-La Roche Ltd and Gensymze; he does not hold stock in any company with interests in nephrology. KFH-Dialysezentren, Nuernberg, has received research grants from F. Hoffmann-La Roche Ltd.

Professor Aljama has received consultancy fees from Amgen, F. Hoffmann-La Roche Ltd, Janssen-Cilag and Shire; he does not hold stock in any company with interests in nephrology. The Hospital Reina Sofia, Servicio de Nefrologia, has received research grants from Amgen, F. Hoffmann-La Roche Ltd, Janssen-Cilag and Shire.

Professor Kerr has received honoraria and consultancy fees from Amgen Australia, Fresenius Medical Care and F. Hoffmann-La Roche Ltd; he does not hold stock in any company with interests in nephrology. The Department of Nephrology, Monash Medical Centre has received research grants from Amgen Australia and F. Hoffmann-La Roche Ltd.

Professor Locatelli has received honoraria and consultancy fees from Amgen, Astellas, F. Hoffmann-La Roche Ltd and Shire Pharmaceutical; he does not hold stock in any company with interests in nephrology. The Divisione di Nefrologia e Dialisi, Azienda Ospedale di Lecco has received research grants from Amgen, F. Hoffmann-La Roche Ltd and Shire Pharmaceuticals.

Professor Villa has no financial relationships with any pharmaceutical company and does not hold stock in any company with interests in nephrology.

Dr Van Vlem has received honoraria and consultancy fees from Amgen, F. Hoffmann-La Roche Ltd, Janssen-Cilag and Novartis; he does not hold stock in any company with interests in nephrology. The Department of Nephrology, Dialysis and Hypertension, O.L. Vrouw Ziekenhuis has received research grants from Amgen, F. Hoffmann-La Roche Ltd, Janssen-Cilag and Novartis.

Dr McMahon has received honoraria and consultancy fees from Amgen, AstraZeneca, Bristol-Myers-Squibb, F. Hoffmann-La Roche Ltd, Ortho Biotech, Novartis and SanoFli-Aventis; he does not hold stock in any company with interests in nephrology. The University of Alberta Hospital has received research grants from Amgen, AstraZeneca, F. Hoffmann-La Roche Ltd and Ortho Biotech.

Ms Kerloeguen and Dr Beyer are employees of F. Hoffmann-La Roche Ltd; they do not hold stock in any company with interests in nephrology.
References

1. Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004; 65: 1864–1869

2. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181–1191

3. Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 2003; 18 (Suppl 2): i7–i12

4. Muntner P, He J, Astor BC et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529–538

5. Gerson A, Hwang W, Fiorenza J et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 2004; 44: 1017–1023

6. Perlman RL, Finkelstein FO, Liu L et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005; 45: 658–666

7. Locatelli F, Pisoni RL, Akizawa T et al. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns study (DOPPS) findings. Am J Kidney Dis 2004; 44 (Suppl 2): 27–33

8. Xue JL, Ma JZ, Louis TA et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753–2758

9. Roderick P, Davies R, Jones C et al. Simulation model of renal replacement therapy: predicting future demand in England. Nephrol Dial Transplant 2004; 19: 692–701

10. De Cock E, Van Bellingham L, Standaert B. Assessing provider time for anaemia management of dialysis patients using time & motion methods: a multi-centre observational study in Europe. Value Health 2002; 5: 581

11. Mcdougall IC. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005; 4: 436–440

12. Jarsch M, Brandt M, Lanzendörfer M et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008; 81: 63–69

13. Macdougall IC, Robson R, Opatrna S et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1211–1215

14. Locatelli F, Villa G, de Francisco ALM et al. on behalf of the BA16286 Study Investigators. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 2007; 23: 969–979

15. Levin NW, Fishbane S, Valdés Cañedo F et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370: 1415–1421

16. Sulowicz W, Locatelli F, Ryckelynck J-P et al. on behalf of the PROTOS study investigators. Once-monthly subcutaneous C.E.R.A. maintains stable haemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2: 637–646

17. Locatelli F, Aljama P, Bárány P et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2): i1–i47

18. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease. 2000. Am J Kidney Dis 2001; 37(Suppl 1): S182–S238

19. Singh AK, Szczek L, Tang KL et al. CHOIR Investigators. Correction of anaemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–2098

20. Drueke TB, Locatelli F, Clyne N et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071–2084

21. Tolman C, Richardson D, Bartlett C et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol 2005; 16: 1463–1470

22. Port FK, Pisoni RL, Bragg-Gresham JL et al. DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 2004; 22: 175–180

Appendix

STRIATA study investigators: P. Aljama, R. Bigazzi, A. H. Bock, J. Bonal Bastons, C. Bovy, J. Braun, B. Canaud, A. Cases, J. H. Christensen, J.-M. Cisterne, A. L. M. de Francisco, H. Dieperink, E. Gago, F. Giacardy, E. Goffin, T. Hannedouche, H. Holzer, P. Jaeger, J. Jastrzebski, D. Johnson, S. Jolly, L. Kairaitis, P. G. Kerr, V. Kliem, P. Koskinen, F. Locatelli, A. McMahon, G. Mingardi, G. Mortis, O. V. Oestergaard, G. Remuzzi, S. Roger, D. Sarn Guajardo, V. Savica, S. D. Soroka, M. Suranyi, J. M. Tabernero, C. Tielemans, P. Urena Torres, B. Van Vlem, G. Villa, B. von Albertini, R. Walker, C. Warholm, T. Weinreich, L. G. Weiss, C. Wijeyesinghe, G. K. T. Wong, J. M. Zacharias.

Received for publication: 19.9.07
Accepted in revised form: 19.5.08